Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus KERLEDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus KERLEDEX.
CORTIFOAM vs KERLEDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Category C
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination